NASH drug helps reduce liver fat with good tolerability

Patients with non-alcoholic steatohepatitis treated with BIO89-100 experienced clinically meaningful reduction in liver fat, according to research presented at The Liver Meeting Digital Experience.“We conducted a randomized, placebo-controlled trial using 89Bio’s glycoPEGylated FGF21 compound,” study investigator Rohit Loomba, MD, MHSc, director of the University of California, San Diego NAFLD Research Center told Healio Gastroenterology. “We looked at several different doses of FGF21 and also used weekly vs. every-two-weeks dosing.”Researchers assessed the drugRead More

Share on facebook
Share on twitter
Share on linkedin